Join
Live feed
·
PRReleasevia Quantisnow
Seres Therapeutics Inc. logo

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

ByQuantisnow·Wall Street's wire, on your screen.
MCRB· Seres Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MCRB (Seres Therapeutics Inc.) and more on Quantisnow.